Research programme: anti-GARP monoclonal antibodies - argenx

Drug Profile

Research programme: anti-GARP monoclonal antibodies - argenx

Alternative Names: ARGX-115

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator Catholic University of Louvain; Ludwig Institute for Cancer Research
  • Developer argenx; Catholic University of Louvain
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Apr 2016 arGEN-X and Abbvie agree to co-develop and co-commercialise ARGX 115 for Cancer
  • 13 Oct 2015 ArGEN-X excerised option to license ARGX 115
  • 18 Feb 2015 arGEN-X in-licenses GS Xceed™ System technology from Lonza
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top